Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks

By Sean Williams - Mar 20, 2014 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P makes up nearly all of yesterday's lost ground, while Sinovac, Burlington, and ZIOPHARM all rise by double digits.

Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 ( ^GSPC -1.18% ) higher, practically erasing almost all of yesterday's losses.

As per the norm, we got initial weekly jobless claims data today, which showed a less than 2% increase to a seasonally adjusted 320,000. In a perfect world, we never want to see jobless claims rise, but a figure of 320,000 appears low enough to warrant an ongoing drop in the unemployment rate.

What really seemed to invigorate investors today was a surprising 0.5% jump in leading indicators for February after a tame 0.1% rise in January, and a 0.1% decline in December. This big jump gives investors hope that the U.S economy will rebound voraciously from its early season weather-induced slump.

On the flip side, existing home sales data continues to be weak. February's data showed a decline of 0.4% to a seasonally adjusted annual rate of 4.6 million, matching economists' expectations, but also hitting their lowest levels since July 2012. Although low inventories are helping home prices, the precarious drop in mortgage originations anytime interest rates have even the slightest uptick is concerning.

Despite the mixed data, the S&P 500 pushed higher by 11.24 points (0.60%) to close at 1,872.01.

Topping the charts today was China-based infectious disease vaccine developer Sinovac Biotech ( SVA ), which jumped 17.1% after reporting its fourth-quarter results. For the quarter, Sinovac saw sales increase 17%, to $22.9 million, as it reported net income of $0.10 per share compared to a net loss of $0.08 per share in Q4 last year. By comparison, Wall Street was looking for Sinovac to report a loss of $0.01 per share, so this was a sizable beat. While sales of comparable products (e.g., hepatitis and influenza vaccines) actually fell 19% year over year, the addition of an H5N1 vaccine produced $7.2 million in revenue, which helped propel Sinovac higher. It's hard to argue against a company focused on treating infectious diseases given that so many countries around the world still lack access to these basic vaccines, but at 50 times forward earnings, much of that optimism may already be baked into Sinovac's share price.

Sticking with our theme of earnings-driven events, discount branded retail and accessories chain Burlington Stores ( BURL -4.25% ) gained 15.8% after reporting market-topping profits in the fourth quarter. Profit for the quarter dipped to $1.07 per share from $1.15 in the year-ago quarter, but handily surpassed the $1.03 per share that Wall Street expected. The results, though, were largely mixed, with comparable-store sales growing 4% during the quarter and signaling robust growth; yet, its first-quarter EPS forecast of $0.19-$0.23 in EPS bracketed a bit lower than Wall Street's forecast of $0.23 per share. Overall, I'm a bit put off by Burlington, which is valued at 21 times forward earnings, and is only forecasting same-store sales growth of 2%-3% in the upcoming year. I believe there are considerably more attractive places to put your money to work in the retail sector.

Finally, clinical-stage biopharmaceutical company ZIOPHARM Oncology ( ZIOP -8.63% ) jumped 11.8% following a rating initiation from Mizuho Financial Group. Mizuho, in a research note released last night, started ZIOPHARM with a buy rating and an $11 price target, implying 127% potential upside based on yesterday's close. Mizuho notes that ZIOPHARM's exclusive use of Intrexon's ( PGEN -2.28% ) RheoSwitch Therapeutic System for use in developing new oncology-based therapies could give it a unique advantage that may result in positive readouts this year. While ZIOPHARM's pipeline does offer promise, I remain cautious about that it only has two ongoing phase 2 clinical studies, and a number of preclinical studies. Until its pipeline becomes more mature, I'd prefer to stay on the sidelines.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,513.04 (-1.18%) $-53.96
ZIOPHARM Oncology, Inc. Stock Quote
ZIOPHARM Oncology, Inc.
ZIOP
$1.27 (-8.63%) $0.12
Sinovac Biotech Ltd. Stock Quote
Sinovac Biotech Ltd.
SVA
Precigen, Inc. Stock Quote
Precigen, Inc.
PGEN
$3.85 (-2.28%) $0.09
Burlington Stores, Inc. Stock Quote
Burlington Stores, Inc.
BURL
$280.66 (-4.25%) $-12.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.